Melanoma Vaccine Reduces Recurrence Risk by 42%

• A new melanoma vaccine developed by Moderna and Merck has shown promising results.
• The vaccine reduces the risk of melanoma recurrence by 42%.
• The vaccine is an mRNA-based treatment, a technology also used in COVID-19 vaccines.
• The results were shared in a clinical trial involving patients who had previously been treated for melanoma.
• Moderna's stock experienced a significant drop following the release of the vaccine data.